Pipeline
Iconovo’s pipeline outlines the development progress of each platform and project, highlighting the path forward in collaboration with our partners.
1
2
3
4
5
6
7
8
1
Development of a substitutable generic version of AstraZeneca’s Symbicort Turbuhaler
Iconovo has developed ICOres, a dry powder inhaler that is substitutable for AstraZeneca’s Turbuhaler and a combination formulation of the anti-inflammatory budesonide and reliever formoterol. The product has been compared to Symbicort Turbuhaler in three pilot pharmacokinetic studies. The most recent study showed that the product would meet the criteria for demonstrating bioequivalence in an appropriately designed and powered study. The product is licensed to Amneal Pharmaceuticals.
2
Development of a generic multi-dose inhaler product to treat asthma and COPD
Iconovo has developed a generic inhalation product for the treatment of asthma and COPD utilizing ICOres, a multi-dose dry powder inhaler. This product includes both the inhaler device and a dry powder formulation, developed to serve as a generic alternative to a non-disclosed product. The product development is finalized after showing comparable in-vitro characteristics to the reference product and is ready to enter the first pilot pharmacokinetic study. The product is licensed to Intas Pharmaceuticals.
3
Development of a substitutable generic version of GSK’s Breo/Relvar Ellipta
Iconovo has developed ICOpre, a dry powder inhaler that is substitutable for GSK’s Ellipta inhaler, along with a combination formulation of the anti-inflammatory drug fluticasone furoate and the bronchodilator vilanterol. After showing comparable in-vitro characteristics, the product is ready for a first pilot pharmacokinetic study. The plan is to develop the entire portfolio of Ellipta products. The product is currently undergoing an out-licensing process.
4
Development of a generic version of Novartis’ Ultibro Breezhaler
Iconovo has developed the capsule-based inhaler ICOcap, which has the same attractive properties as Breezhaler, and a combination formulation of indacaterol and glycopyrronium—two bronchodilators with different modes of action. After showing comparable in-vitro characteristics, the pharmaceutical product development is finalized and ready to enter the first pilot pharmacokinetic study. The product is licensed to BNC Korea for an Asian territory and is available for partnering in the EU.
5
Development of an inhalation product using an FDA-approved active pharmaceutical ingredient that has been reformulated from another delivery method
The project aims to develop a new treatment for interstitial lung disease. Iconovo develops the formulation for use in ICOcap, a robust patient-friendly capsule inhaler. The pharmaceutical product is being developed for Kiox Pharma.
6
Development of an intranasal semaglutide (GLP-1) for the treatment of obesity that will compete with today’s injectable GLP-1 products
Iconovo has developed ICOone Nasal, a unique single-dose inspiratory-flow-driven nasal delivery device. The company is currently developing a semaglutide-based formulation tailored for the device. Iconovo will explore the systemic availability when administering the product nasally. The product will be developed to preclinical proof of concept before being partnered. This is Iconovo’s first reformulation project to be developed in-house.
7
Development of an inhaled oxytocin product for the treatment of postpartum haemorrhage (PPH) – excessive bleeding after birth
Iconovo has developed ICOone with a smart, one-piece design that minimizes manufacturing cost and allows for the delivery of biologics and vaccines. The formulation has been developed by Monash University, which has licensed the device for this use. The project is currently in clinical development.
8
Feasibility study to manufacture Affilogic’s Nanofitin formulation as an inhaled product using ICOone
Iconovo has developed ICOone with a smart, one-piece design that minimizes manufacturing cost and allows for the delivery of biologics and vaccines. Iconovo developed a formulation containing Affilogic’s biologic antiviral Nanofitin construct to be inhaled using ICOone. The results of the feasibility study were positive and have been presented as a poster at RDD 2024. This proof-of-concept study demonstrates that biologics can be delivered locally to the lungs using ICOone.
Follow us on Linkedin
